Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Connecticut Judge Dismisses Opioid Drug Lawsuits

A judge dismissed lawsuits filed by 37 different municipal governments pertaining to opioid drugmakers being sued in the state of Connecticut.

Read More »

Pear Therapeutics receives $64 million in Temasek-led funding

Privately held Pear Therapeutics said the company raised $64 million from investors, including Singapore’s Temasek Holdings, weeks after launching a mobile app for treating patients with substance use disorder.

Read More »

Former Insys executive pleads guilty to opioid bribe scheme

A former executive at Insys Therapeutics Inc. pleaded guilty to participating in a scheme to bribe doctors to prescribe the company’s powerful opioid medication and entered into a deal to cooperate with prosecutors.

Read More »

FDA to ban flavored e-cigs at U.S. convenience stores

The FDA announced sweeping new restrictions on flavored tobacco products, including electronic cigarettes popular among teenagers in an effort to prevent a new generation of nicotine addicts.

Read More »

New Jersey Sues Janssen Over Two Opioid Drugs

State officials from New Jersey took aim at Johnson & Johnson subsidiary Janssen by filing a lawsuit pertaining to the marketing of opioids.

Read More »

As states chase sports betting gold, addicts left in the cold

A growing number of publicly funded programs face a financial crunch as U.S. states jump at the chance to collect revenue through legal sports betting, while largely ignoring the need to spend more tackling gambling addiction.

Read More »

Pfizer and Lilly non-opioid drug helps reduce osteoarthritis pain

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

Read More »

Indivior slashes 2018 revenue outlook for Sublocade

Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.

Read More »

Senate Overwhelmingly Passes Bill to Address Prescription Opioids

The U.S. Senate overwhelmingly supported a new bill aimed at opioid abuse and other addictive drugs.

Read More »

FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain

Concentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom